Read by QxMD icon Read

Breast cancer, treatment

Weijun Xu, Junmin Qian, Guanghui Hou, Yaping Wang, Jinlei Wang, Tiantian Sun, Lijie Ji, Aili Suo, Yu Yao
Integration of multimodal therapies into one nanoplatform holds great promise to overcome the drawbacks of conventional single-modal therapy and pursues enhanced anticancer efficacy. Herein, we developed a PEGylated gold nanorods (GNRs)-based nanoplatform (GNRs-MPH-ALA/DOX -PEG) with pH-responsive drug release property for triple-combined chemotherapy (CT), photodynamic therapy (PDT) and photothermal therapy (PTT) of breast cancer. GNRs were first decorated with mercaptopropionylhydrazide (MPH) and thiol-terminated monomethoxyl poly(ethylene glycol) (mPEG-SH) via Au-thiol linkage, and subsequently conjugated with chemotherapeutant doxorubicin (DOX) and pro-photosensitizer 5-aminolevulinic acid (ALA) through acid-liable hydrazone bonds between drugs and MPH molecules...
October 15, 2018: Acta Biomaterialia
Ying-Sheng Xiao, De Zeng, Yuan-Ke Liang, Yang Wu, Mei-Fang Li, Yu-Zhu Qi, Xiao-Long Wei, Wen-He Huang, Min Chen, Guo-Jun Zhang
Resistance to chemotherapy remains a significant problem in the treatment of breast cancer, especially for triple-negative breast cancer (TNBC), in which standard systemic therapy is currently limited to chemotherapeutic agents. Our study aimed to better understand the molecular mechanisms that lead to failure of chemotherapy in TNBC. Herein, we observed elevated expression of Notch1 and major vault protein (MVP) in MDA-MB-231DDPR cells compared to their parental counterparts. We demonstrated that Notch1 could positively regulate the expression of MVP...
October 15, 2018: Cancer Letters
Vahid Kia, Mahdi Paryan, Yousef Mortazavi, Alireza Biglari, Samira Mohammadi-Yeganeh
Breast cancer is one of the most prevalent cancers in women. Triple-negative breast cancer consists 15% to 20% of breast cancer cases and has a poor prognosis. Cancerous transformation has several causes one of which is dysregulation of microRNAs (miRNAs) expression. Exosomes can transfer miRNAs to neighboring and distant cells. Thus, exosomal miRNAs can transfer cancerous phenotype to distant cells. We used gene expression omnibus (GEO) datasets and miRNA target prediction tools to find overexpressed miRNA in breast cancer cells and their target genes, respectively...
October 18, 2018: Journal of Cellular Biochemistry
Madhusmita Rout, Sajitha Lulu S
Discerning the relationship between molecules involved in diseases based on their underlying biological mechanisms is one of the greatest challenges in therapeutic development today. Gestational diabetes mellitus (GDM) is one of the most common complications during pregnancy, which adversely affects both mothers and offspring during and after pregnancy. We have constructed two datasets of (GDM associated genes from affected mother and placenta to systematically analyze and evaluate their interactions like gene-gene, gene-protein, gene-microRNA (miRNA), gene-transcription factors, and gene-associated diseases to enhance our current knowledge, which may lead to further advancements in disease diagnosis, prognosis, and treatment...
October 18, 2018: Journal of Cellular Biochemistry
Juan Li, Jie Liu, Pingping Li, Can Zhou, Peijun Liu
WW domain-containing oxidoreductase (WWOX), an important tumor suppressor, is essential for regulating cell proliferation and apoptosis. Our study demonstrates that low level of WWOX is associated with the triple-negative subtype of breast cancer (TNBC), which has higher stem cell phenotype and chemoresistance. We evaluated the role of WWOX in regulation of breast cancer stem cells (BCSC) phenotype and chemoresistance. Our results showed that knockdown of WWOX increases the stemness of breast cancer cells. Meanwhile, downregulation of WWOX induces the epithelial-mesenchymal transition (EMT) and chemoresistance of breast cancer cell lines...
October 18, 2018: Experimental Biology and Medicine
Ke Yang, Xiang Yang, Xiang Zhao, Marc Lamy de la Chapelle, Weiling Fu
Simple, rapid, and efficient cell viability assay plays a fundamental role in many biomedical researches, including the cell toxicology investigation and antitumor drug screening. Here, we demonstrate for the first time a rapid and label-free cell viability assay using THz spectroscopy in combination with a new optical clearing agent (OCA) and microfluidic technology. This strategy uses a considerably less absorptive OCA to replace the highly absorptive water molecules around the living cells, and thus to decrease the background signal interference...
October 18, 2018: Analytical Chemistry
Ana Helena Perea, Diego Rosselli
Introduction. Breast reconstruction, either immediate or delayed, is part of the treatment of breast cancer. Each country and health system pays for and evaluates these procedures in different ways. Thus, it is important to determine which strategy is most cost-effective in Colombia. Objective: To evaluate the cost-utility of breast cancer treatment with immediate reconstruction compared with delayed reconstruction. Materials and methods: We used a decision tree model and a one-year time horizon from the perspective of the third-party payer; the cost data were taken from the Colombian Instituto de Seguros Sociales 2001 rate manual plus a 30% adjustment according to the methodology of the Instituto de Evaluación Tecnológica en Salud, IETS, and the billing model of the Centro Javeriano de Oncología at the Hospital Universitario San Ignacio...
September 1, 2018: Biomédica: Revista del Instituto Nacional de Salud
Yuan Chen, Rui Zhu, Fang Ma, Jialin Mao, Eugene C Chen, Edna Choo, Srikumar Sahasranaman, Lichuan Liu
GDC-0810 was under development as an oral anti-cancer drug for the treatment of estrogen receptor-positive breast cancer as a single agent or in combination. In vitro data indicated that GDC-0810 is a potent inhibitor of OATP1B1/1B3. To assess clinical risk, PBPK model was developed to predict the transporter drug-drug interaction (tDDI) between GDC-0810 and pravastatin in human. The PBPK model was constructed in Simcyp® by integrating in vitro and in vivo data for GDC-0810. The prediction of human pharmacokinetics (PK) was verified using GDC-0810 phase I clinical PK data...
October 18, 2018: Biopharmaceutics & Drug Disposition
Matteo Lambertini, Samuel Martel, Christine Campbell, Sébastien Guillaume, Florentine S Hilbers, Uwe Schuehly, Larissa Korde, Hatem A Azim, Serena Di Cosimo, Richard C Tenglin, Jens Huober, José Baselga, Alvaro Moreno-Aspitia, Martine Piccart-Gebhart, Richard D Gelber, Evandro de Azambuja, Michail Ignatiadis
BACKGROUND: Limited data exist on the safety of using anti-human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pregnancy after prior early breast cancer, with no data in HER2-positive patients. METHODS: The Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial and the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial were randomized phase 3 trials for patients with HER2-positive early breast cancer...
October 18, 2018: Cancer
Wu Ding, Zhian Li, Caiyun Wang, Jiangfeng Dai, GuoDong Ruan, Chuanjian Tu
PURPOSE: The clinical benefits provided by using anthracycline-contained regimens in patients with early breast cancer (EBC) remain uncertain. This meta-analysis used data from all relevant trials to compare treatment outcomes for patients with EBC receiving adjuvant chemotherapy with non-anthracycline-contained regimens or anthracycline-contained regimens. PATIENTS AND METHODS: Individual patient data were collected on 7 randomized trials comparing non-anthracycline-contained regimens with anthracycline-contained regimens, a total of 14,451 women were analyzed...
October 2018: Medicine (Baltimore)
Sara Ruiz-Pinto, Miguel Martin, Guillermo Pita, Daniela Caronia, Julio C de la Torre-Montero, Leticia T Moreno, Fernando Moreno, José Á García-Sáenz, Javier Benítez, Anna González-Neira
OBJECTIVES: Taxanes and anthracyclines are widely used in the treatment of breast cancer, although the benefit is limited to a proportion of patients and predictive biomarkers for clinical outcome remain elusive. PATIENTS AND METHODS: We carried out a pharmacogenetic study in 181 patients with locally advanced breast cancer enrolled in a phase 2 randomized clinical trial (NCT00123929), where patients were randomly assigned to receive neoadjuvant single-agent docetaxel 100 mg/m (n=84) or doxorubicin 75 mg/m (n=97)...
November 2018: Pharmacogenetics and Genomics
Hoda S Hashemi, Stefanie Fallone, Mathieu Boily, Anna Towers, Robert D Kilgour, Hassan Rivaz
Breast cancer-related lymphedema (BCRL) is a consequence of a malfunctioning lymphatic drainage system resulting from surgery or some other form of treatment. In the initial stages, minor and reversible increases in fluid volume of the arm are evident. As the stages progress over time, the underlying pathophysiology dramatically changes with an irreversible increase in arm volume most likely due to a chronic local inflammation leading to adipose tissue hypertrophy and fibrosis. Clinicians have subjective ways to stage the degree and severity such as the pitting test which entails manually comparing the elasticity of the affected and unaffected arms...
October 15, 2018: IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control
Victoria Speed, Lara N Roberts, Jignesh P Patel, Roopen Arya
The prevention and treatment of venous thromboembolism (VTE) poses distinct gender-specific challenges. Women of childbearing age are at an increased risk of VTE secondary to the transient risk factors of combined hormonal contraception (CHC) and pregnancy. Cancers specific to women are associated with a significant burden of VTE; whilst the incidence of VTE in localised breast cancer is 5 per 1000 person-years, more cases are seen due to the prevalence of breast cancer. Treatment of VTE in women can be complicated by abnormal uterine bleeding, now increasingly reported with direct oral anticoagulants (DOACs) as well as vitamin K antagonists...
October 18, 2018: British Journal of Haematology
Mang Mang Sang, Fu Lei Liu, Yang Wang, Ren Jie Luo, Xiao Xian Huan, Ling Fei Han, Zhong Tao Zhang, Feng Feng, Wei Qu, Wenyuan Liu, Feng Zheng
Gambogic acid (GA) is a naturally derived potent anticancer agent with extremely poor biocompatibility. In the present study, a novel of redox/pH dual-responsive multifunctional magnetic complex micelle (sPEG/HA/CSO-SS-Hex/Fe3 O4 /GA), which consisted of a reducible hexadecanol-modified chitosan oligosaccharide polymer micelle (CSO-SS-Hex) coated with hyaluronic acid (HA) and DCA grafted sheddable PEG-PLL (sPEG) copolymers and loaded with gambogic acid (GA) and Fe3 O4 nanoparticles were developed for parenteral delivery for the treatment of triple negative breast cancer (TNBC)...
November 2018: Drug Delivery
X Song, J Q Wu, X F Yu, X S Yang, Y Yang
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor outcome. Because of lacking therapeutic targets, chemotherapy is the main treatment option for patients with TNBC. Overexpression of HDACs correlates with tumorigenesis, highlighting the potential of HDACs as therapeutic targets for TNBC. Here we demonstrate that trichostatin A (TSA, a HDAC inhibitor) selectively inhibits the proliferation of TNBC cell lines HCC1806 and HCC38 rather than a normal breast cell line MCF10A...
September 4, 2018: Neoplasma
Yingxiang Hou, Xin Li, Qianhua Li, Juntao Xu, Huijie Yang, Min Xue, Gang Niu, Shu Zhuo, Kun Mu, Gaosong Wu, Xiumin Li, Hui Wang, Jian Zhu, Ting Zhuang
Oestrogen receptor α (ERα) is overexpressed in two-thirds of all breast cancer cases and is involved in breast cancer development and progression. Although ERα -positive breast cancer can be effectively treated by endocrine therapy, endocrine resistance is an urgent clinical problem. Thus, further understanding of the underlying mechanisms involved in ERα signalling is critical in dealing with endocrine resistance in patients with breast cancer. In the present study, unbiased RNA sequence analysis was conducted between the MCF-7 and MCF-7 tamoxifen-resistant (LCC2) cell lines in order to identify differentially expressed genes...
October 17, 2018: Journal of Cellular and Molecular Medicine
Lufang Zhang, Lushan Wang, Dong Dong, Zhiyong Wang, Wei Ji, Man Yu, Fei Zhang, Ruifang Niu, Yunli Zhou
OBJECTIVES: MiR-34 is a tumour suppressor in breast cancer. Neurokinin-1 receptor (NK1R), which is the predicted target of the miR-34 family, is overexpressed in many cancers. This study investigated the correlation and clinical significance of miR-34 and NK1R in breast cancer. MATERIALS AND METHODS: Western blotting, quantitative reverse transcription-PCR (qRT-PCR) and luciferase assays were conducted to analyse the regulation of NK1R by miR-34 in MDA-MB-231, MCF-7, T47D, SK-BR-3 and HEK-293 T cells...
October 17, 2018: Cell Proliferation
Hannah M Pezzi, David J Guckenberger, Jennifer L Schehr, Jacob Rothbauer, Charlotte Stahlfeld, Anupama Singh, Sacha Horn, Zachery D Schultz, Rory M Bade, Jamie M Sperger, Scott M Berry, Joshua M Lang, David J Beebe
Rare cell populations provide a patient-centric tool to monitor disease treatment, response, and resistance. However, understanding rare cells is a complex problem, which requires cell isolation/purification and downstream molecular interrogation - processes challenged by non-target populations, which vary patient-to-patient and change with disease. As such, cell isolation platforms must be amenable to a range of sample types while maintaining high efficiency and purity. The multiplexed technology for automated extraction (mTAE) is a versatile magnetic bead-based isolation platform that facilitates positive, negative, and combinatorial selection with integrated protein staining and nucleic acid isolation...
October 18, 2018: Lab on a Chip
Mathilde Guerin, Anthony Gonçalves, Yves Toiron, Emilie Baudelet, Matthieu Pophillat, Samuel Granjeaud, Patrick Fourquet, William Jacot, Carole Tarpin, Renaud Sabatier, Emilie Agavnian, Pascal Finetti, José Adelaide, Daniel Birnbaum, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Patrice Viens, François Bertucci, Jean-Paul Borg, Luc Camoin
Introduction: treatments targeting the Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2) have improved the natural history of HER2-positive breast cancer. However, except HER2 protein expression and gene amplification, there is no predictive biomarker to guide the HER2-targeted therapies. We developed Parallel reaction monitoring (PRM) a powerful approach, to quantify and evaluate key proteins involved in the HER2 pathway and/or anti-HER2 treatment sensitivity. Results: in BCLs, PRM measurements correlated with western blot immunocytochemistry and transcriptomic data...
September 18, 2018: Oncotarget
Hirotaka Suga, Tomohiro Shiraishi, Akihiko Takushima
Objective: During 2-stage breast reconstruction in patients with unilateral breast cancer, we sometimes experience cases in which the contralateral breast volume changes greatly. However, few studies have examined volumetric changes in the contralateral breast during 2-stage breast reconstruction. Methods: Changes in contralateral breast volume between the first and second operations were examined in patients who underwent 2-stage unilateral breast reconstruction between February 2013 and August 2016 (123 patients aged 49...
2018: Eplasty
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"